MTA-cooperative PRMT5 inhibitors (Ryvu Therapeutics)

N/A

Report date: 2025/03/20 14:39:48
NME

Base Information

Drug NameMTA-cooperative PRMT5 inhibitors (Ryvu Therapeutics)
Drug Alias NamePRMT5 inhibitors (Ryvu Therapeutics)MTAP deleted cancer therapy (Ryvu Therapeutics)MTAP deleted cancer therapy (Selvita)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein arginine methyltransferase 5 inhibitors
TargetsProtein arginine methyltransferase 5
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPoland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A